project id: TCGA-PRAD; case submitter id: TCGA-VN-A88L; source center: 23; state: released; a260 a280 ratio: 1.91; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.14; rna integrity number: 7.5; age at index: 54; days to birth: -20026; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1958; age at diagnosis: 20026; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 746.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 367; initial weight: 130.0; sample id: bec25345-82c0-465e-a1c5-f73bdd2fc4ae; sample submitter id: TCGA-VN-A88L-01A; portion id: 4ba6f01a-a0f1-40f8-802e-9918a405f9bc; portion submitter id: TCGA-VN-A88L-01A-11; slide id: 597c5a27-c448-466c-8144-2c8c9166176a; slide submitter id: TCGA-VN-A88L-01A-01-TS1; percent lymphocyte infiltration: 60.0; percent monocyte infiltration: 10.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0; section location: TOP;